The global allergy diagnostics and therapeutics market size is likely to be valued at US$41.5 billion in 2026 and is expected to reach US$88.3 billion by 2033, growing at a CAGR of 11.4% during the forecast period from 2026 to 2033, driven by the rising global burden of allergic diseases associated with urbanization and environmental exposure. Increasing adoption of precision diagnostics such as component-resolved testing is improving early and accurate detection rates. Expanding use of biologics and immunotherapy is also strengthening long-term treatment demand.

Driver - Urban Pollution as a Key Allergy Trigger

Rapid urbanization is constantly expanding the pool of allergy patients. In dense cities, vehicle exhaust and industrial emissions release fine particulates and ground-level ozone. These pollutants irritate airways and amplify the immune response to pollen, mold, and dust. A World Health Organization (WHO) report from May 2024 noted that air pollution is a key risk factor for asthma, which affects nearly 262 million people globally.

A January 2025 review published in Frontiers in Allergy further confirmed that both indoor and outdoor pollutants are intensifying respiratory allergies such as asthma and rhinitis. Climate change is worsening seasonal allergy patterns through altered weather and high pollen output. As more people shift to urban settings, the demand for diagnostic testing and treatment continues to rise.

Shift toward Disease Modification Over Symptom Control

Allergy care has moved well beyond antihistamines and steroid sprays. Allergen-specific immunotherapy (AIT), delivered as sublingual tablets or oral drops, works by gradually retraining the immune system to tolerate allergens rather than just suppressing reactions. Between 2005 and 2025, the field of food allergy therapeutics saw a key expansion of clinical trials exploring oral, sublingual, and epicutaneous immunotherapies.

In 2024, omalizumab received an expanded indication for reducing allergic reactions from accidental food exposure, adding to a surging toolkit for long-term disease management. This pivot from short-term relief to durable immune tolerance is a core reason why the therapeutics segment is expanding swiftly.

Restraint - False Positives or Sensitization May Hamper Demand

One of the most underappreciated problems in allergy diagnostics is the difference between sensitization and a true clinical allergy. Skin Prick Tests (SPT) and blood IgE tests detect immune memory to a substance. However, that does not confirm the person will actually react to it. As noted by National Institutes of Health (NIH)-published research, positive skin prick test results can occur in people without symptoms. Also, blanket allergy testing, especially for foods, can lead to unnecessary dietary restrictions.

In food allergy testing, particularly, more false positive results are observed with skin prick testing, while over 95% of patients who test negative on skin prick tests for food do not show immediate allergic symptoms. This gap between test results and real clinical outcomes undermines physician confidence in testing protocols. It can also delay correct diagnosis, expose patients to avoidable dietary or lifestyle restrictions, and erode trust in the diagnostic process, thereby slowing wide adoption of allergy testing.

Opportunity - AI to Bring Standardization to Patch Testing

Patch testing for contact dermatitis has long depended on specialist interpretation, making it prone to variability across clinicians. AI is changing this. A 2025 review published in JMIR Dermatology (UCLA) found that convolutional neural network models used for patch test image analysis achieved accuracy rates ranging from 90.1% to 99.5%. More practically, Mayo Clinic's Jacksonville facility developed a smartphone-based AI tool in 2025 to streamline patch test reading.

It aims to reduce repeated clinic visits and address the shortage of dermatology specialists in rural areas. These tools lower the barrier to diagnosis in underserved regions and reduce the subjectivity that currently limits the reliability of contact dermatitis workups. As imaging protocols become standardized, AI-assisted diagnostics are poised to become a routine part of allergy clinical workflows.

Next-Generation Biologics to Move Beyond IgE Blockade

The biologic space for allergic conditions has become significantly more precise. Early options such as omalizumab targeted IgE broadly, but new monoclonal antibodies act on specific inflammatory cytokine pathways. In 2025, the FDA approved tezepelumab for chronic rhinosinusitis with nasal polyps, adding to its existing indication for severe asthma. This made it one of the few biologics approved across multiple inflammatory airway diseases.

Approved biologics now include agents that block IL-5/IL-5Rα (mepolizumab, benralizumab), IL-4Rα (dupilumab), TSLP (tezepelumab), and IgE (omalizumab), each suited to different patient endotypes. This endotype-based approach allows physicians to match treatment to a patient's specific inflammatory profile. It further helps in improving outcomes in populations that previously had no effective options beyond corticosteroids.

Product Type Insights

Therapeutics is predicted to lead with a share of approximately 83.3% in 2026, as allergy is usually a long-term condition that requires continuous symptom control and disease management. Diagnostic tests are generally performed once or a few times, but medications such as antihistamines, corticosteroids, biologics, and immunotherapies are used repeatedly over months or years. This creates sustained demand for therapeutic products. Another important driver is the surging adoption of allergen immunotherapy. Unlike conventional drugs that only suppress symptoms, immunotherapy addresses the underlying immune response.

The diagnostic segment is estimated to be the fastest-growing segment over the forecast period, as healthcare providers are moving away from broad allergy identification and toward precise allergen characterization. Patients increasingly want to know exactly which molecule, pollen, food protein, or drug component is causing the reaction. This has created demand for advanced molecular diagnostics. Another factor is the rise of personalized medicine. Allergy specialists now use molecular diagnostics before initiating expensive biologic therapies or immunotherapy programs.

Allergen Type Insights

Inhaled allergies are anticipated to dominate with a share of nearly 51.6% in 2026, as exposure to airborne allergens is unavoidable and occurs daily. People continuously inhale pollen, dust mites, mold spores, pet dander, and environmental pollutants at home, school, workplaces, and public spaces. This constant exposure makes respiratory allergies much more common than food or drug allergies. Allergic rhinitis is one of the most widespread allergic conditions globally. Recent health data indicate that more than 400 million people worldwide experience allergic rhinitis, largely propelled by airborne allergens such as pollen, dust mites, and pet dander.

Drug allergies are expected to remain in the second position in 2026, as medication use is increasing worldwide. Aging populations, chronic disease management, and easy access to healthcare have led to high consumption of antibiotics, biologics, cancer therapies, and specialty medicines. Greater exposure naturally increases the likelihood of allergic reactions and hypersensitivity events. A key growth driver is the increasing recognition of previously undiagnosed drug allergies. Healthcare providers are actively investigating antibiotic allergy labels as several patients are incorrectly classified as allergic.

North America Allergy Diagnostics and Therapeutics Market Trends

North America is predicted to lead in 2026 with a share of approximately 38.8%, owing to the surging clinical awareness and early diagnosis of allergies. A large share of patients undergoes confirmatory testing instead of self-medication. According to the Centers for Disease Control and Prevention (CDC), allergies are among the most common chronic conditions in the U.S., with millions affected by hay fever, food allergies, and asthma. This high-diagnosed patient pool supports demand for both diagnostics and therapies.

U.S. Allergy Diagnostics and Therapeutics Market Trends

A share of nearly 64.3% is expected to be held by the U.S. in 2026, backed by rising food and drug allergy cases. According to the National Institute of Allergy and Infectious Diseases, food allergies affect around 32 million Americans, including many children. This is increasing demand for both testing and long-term treatment. Another driver is innovation in biologics. Drugs such as omalizumab are now being used beyond asthma, including food allergies. From 2024 to 2025, NIH-supported studies showed improved tolerance outcomes in multi-food allergy patients treated with biologics. This is shifting treatment patterns toward high-value therapies.

Asia Pacific Allergy Diagnostics and Therapeutics Market Trends

Asia Pacific is anticipated to be the fastest-growing market in 2026, with a share of nearly 31.9%, spurred by rapid urbanization and pollution exposure. Cities in India and China are seeing rising pollen levels and air pollution, which increase respiratory allergies. According to the WHO, air pollution is a prominent risk factor for respiratory diseases, including allergic conditions. Another reason is improving healthcare access. Various countries are broadening diagnostic infrastructure and specialist care.

China Allergy Diagnostics and Therapeutics Market Trends

China will likely lead Asia Pacific in 2026 with a share of around 40.1%, due to environmental and lifestyle changes. Studies published in journals such as The Lancet show a sharp rise in childhood allergies in urban Chinese populations. Increased indoor allergen exposure and air pollution are key causes. The government is also strengthening healthcare capacity. Investment in hospital infrastructure and diagnostic labs is extending access to allergy testing.

Japan Allergy Diagnostics and Therapeutics Market Trends

In 2026, Japan is projected to account for a share of approximately 15.4%. Seasonal allergic rhinitis, especially cedar pollen allergy, is very common in the country. Government-backed data indicates that a large portion of the population suffers from pollen allergies every year, making it a major public health issue. Japan is also advanced in treatment adoption. Sublingual immunotherapy is widely used and accepted. The country has approved multiple Sublingual Immunotherapy (SLIT) products for cedar pollen allergy. High awareness and early treatment behavior support consistent demand rather than sudden spikes in growth.

Europe Allergy Diagnostics and Therapeutics Market Trends

Europe will likely see decent growth in the forecast period, with a share of nearly 17.4% in 2026, fostered by structured allergy management systems. Organizations such as the European Academy of Allergy and Clinical Immunology promote standardized diagnosis and treatment guidelines. This ensures consistent use of diagnostics and immunotherapy across countries. Environmental factors also play a key role. Climate change has extended pollen seasons in various parts of Europe. Research published by the European Environment Agency shows that long pollen seasons are increasing allergy symptoms, thereby supporting demand for treatment and testing.

Germany Allergy Diagnostics and Therapeutics Market Trends

Germany will likely register a substantial share of approximately 34.9% in 2026, owing to favorable reimbursement and clinical adoption of immunotherapy. Statutory health insurance covers several allergy treatments, including sublingual and subcutaneous immunotherapy. This reduces the out-of-pocket burden for patients. The country also has a strong base of allergy specialists and research institutions. Local guidelines actively recommend allergen-specific immunotherapy for long-term disease control. This has increased physician confidence and patient uptake.

U.K. Allergy Diagnostics and Therapeutics Market Trends

A share of around 27.5% is predicted to be held by the U.K. in 2026, bolstered by rising allergy prevalence and improved diagnosis. According to the National Health Service (NHS), allergy cases have increased significantly over the past decades, especially among children. There is also a shift toward better allergy management. The NHS is focusing on reducing misdiagnosis, especially in drug allergies. Programs for antibiotic allergy testing are being expanded to improve treatment accuracy. This is predicted to increase demand for diagnostic services and targeted therapies in the next few years.

The global allergy diagnostics and therapeutics market is moderately consolidated with a handful of multinational diagnostics and pharmaceutical companies controlling a significant share of revenue. On the diagnostics side, competition is led by Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, bioMérieux, and HYCOR Biomedical. Thermo Fisher remains the benchmark player through its ImmunoCAP platform, which is widely used for specific IgE testing worldwide.

In therapeutics, the market is dominated by immunotherapy specialists such as ALK-Abelló, Stallergenes Greer, and HAL Allergy, alongside large pharmaceutical companies including Sanofi, AbbVie, GSK, and Teva Pharmaceutical Industries. Competition has shifted from traditional antihistamines toward disease-modifying immunotherapies, especially sublingual tablets and biologics targeting allergic asthma, rhinitis, and atopic diseases. Strategic partnerships, acquisitions, and portfolio expansion remain key competitive strategies.

Key Industry Developments:

• In April 2026, Regeneron and Sanofi announced that the FDA had approved Dupixent for the treatment of children aged two to eleven years with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite antihistamine treatment. Around the same time, the European Commission also approved Dupixent for moderate-to-severe CSU in children aged two to eleven years.
• In October 2025, Amgen and AstraZeneca announced that the FDA approved TEZSPIRE (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and pediatric patients aged 12 years and older. The approval was based on results from the Phase 3 WAYPOINT trial.
• In January 2025, the European Commission approved the extension of Stallergenes Greer's Palforzia (peanut allergen powder) for the treatment of toddlers aged one to three years with a confirmed peanut allergy. The approval covered all 27 EU member states as well as Iceland, Liechtenstein, and Norway.